No Data
No Data
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $270
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $85
EMERGN INTRODUCES PRAXIS BUSINESS & ENTERPRISE: THE GOLD STANDARD FOR PRODUCT MANAGEMENT EXCELLENCE
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
Express News | Needham Reiterates Buy on Praxis Precision Medicine, Maintains $85 Price Target
Promising Future for Praxis Precision Medicines: Buy Rating Backed by Robust Epilepsy Portfolio and Strategic Catalysts